Literature DB >> 15739165

Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases.

Matthew J Thomas1, Alexandra Smith, Denise H Head, Laura Milne, Andrew Nicholls, Wayne Pearce, Bart Vanhaesebroeck, Matthias P Wymann, Emilio Hirsch, Alexandre Trifilieff, Christoph Walker, Peter Finan, John Westwick.   

Abstract

Class I phosphoinositide 3-kinases (PI3K) are known to play a significant role in neutrophil chemotaxis. However, the relative contributions of different PI3K isoforms, and how these impact on lung inflammation, have not been addressed. In vitro studies using wild-type and PI3Kgamma knockout neutrophils demonstrated the major role of the gamma isoform in chemotactic but not chemokinetic events. This was confirmed by a model of direct chemokine instillation into the airways in vivo. Within all studies, a low yet significant degree of neutrophil movement in the absence of PI3Kgamma could be observed. No role for the delta isoform was demonstrated both in vitro and in vivo using PI3Kdelta kinase-dead knock-in mice. Moreover, further studies using the broad-spectrum PI3K inhibitors wortmannin or LY294002 showed no other class I PI3K isoforms to be involved in these chemotactic processes. Here, we identify a contributory PI3K-independent mechanism of neutrophil movement, yet demonstrate PI3Kgamma as the pivotal mediator through which the majority of neutrophils migrate into the lung in response to chemokines. These data resolve the complexities of chemokine-induced neutrophilia and PI3K signaling and define the gamma isoform as a promising target for new therapeutics to treat airway inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739165     DOI: 10.1002/eji.200425634

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 2.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

3.  Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13.

Authors:  Jae Youn Cho; Dae Jae Song; Alexa Pham; Peter Rosenthal; Marina Miller; Shanna Dayan; Taylor A Doherty; Ajit Varki; David H Broide
Journal:  Respir Res       Date:  2010-11-01

4.  Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation.

Authors:  Stephanie Konrad; Syed R Ali; Kristina Wiege; Shahzad N Syed; Linda Engling; Roland P Piekorz; Emilio Hirsch; Bernd Nürnberg; Reinhold E Schmidt; J Engelbert Gessner
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

5.  Targeting lung inflammation: novel therapies for the treatment of COPD.

Authors:  Hongwei Yao; Willem I de Boer; Irfan Rahman
Journal:  Curr Respir Med Rev       Date:  2008

6.  Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation.

Authors:  Matthew Thomas; Matthew J Edwards; Elzbieta Sawicka; Nicholas Duggan; Emilio Hirsch; Matthias P Wymann; Charles Owen; Alexandre Trifilieff; Christoph Walker; John Westwick; Peter Finan
Journal:  Immunology       Date:  2008-08-27       Impact factor: 7.397

7.  PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling.

Authors:  Dae Hyun Lim; Jae Youn Cho; Dae Jin Song; Sang Yeub Lee; Marina Miller; David H Broide
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-11-21       Impact factor: 5.464

8.  The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.

Authors:  Edward Banham-Hall; Menna R Clatworthy; Klaus Okkenhaug
Journal:  Open Rheumatol J       Date:  2012-09-07

9.  The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.

Authors:  Jamil Azzi; Robert F Moore; Wassim Elyaman; Marwan Mounayar; Najib El Haddad; Sunmi Yang; Mollie Jurewicz; Ayumi Takakura; Alessandra Petrelli; Paolo Fiorina; Thomas Ruckle; Reza Abdi
Journal:  Diabetes       Date:  2012-03-08       Impact factor: 9.461

10.  Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.

Authors:  Christopher F Rider; Suharsh Shah; Anna Miller-Larsson; Mark A Giembycz; Robert Newton
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.